Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Inks Cancer Biomarker Deal with J&J

Premium

Foundation Medicine has struck a deal with Johnson & Johnson Pharmaceutical Research and Development to use Foundation's targeted sequencing cancer test to identify potential biomarkers that could be of interest for the pharmaceutical company's clinical oncology programs.

The collaboration is the fourth agreement Foundation has signed with a pharmaceutical company this year, following similar deals with Novartis, Cellgene, and one undisclosed company (CSN 5/17/2011).

"Our test may help identify patients that are more likely to respond to targeted therapies, which could accelerate clinical development and give physicians additional ways to effectively treat patients," said Foundation CEO Michael Pellini in a statement.

Aside from pharmaceutical collaborations, the company is preparing to launch the test, which will sequence more than 200 genes associated with cancer, commercially in the second quarter of 2012 and expects to achieve CLIA certification of its lab by the end of this year (CSN 6/8/2011).

This latest deal follows on the heels of a recent $33.5 million fundraising round to support the commercialization of its test (CSN 10/19/2011).

Financial terms of the deal with J&J were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.